Washington (April 28, 2025) – The American diabetes prevention program, or DPP, reported on April 28, the 21 -year follow -up of this randomized clinical trial showing that the intervention of an original intensive lifestyle has reduced the development of diabetes by 24% and metformin reduced the development of diabetes by 17%.
The DPP had previously shown that after the first 3 years of study, the intensive lifestyle, aimed at moderate weight loss and an increase in physical activity, and the metformin of drugs reduced the start of type 2 diabetes by 58% and 31%, respectively, compared to placebo medicine. All participants were adults at high risk of developing diabetes.
The long -term follow -up of 3 195 participants in the DPP, reported in the medical journal, Lancet Diabetes & Endocrinology highlights the long -term advantages of interventions in the prevention of the development of diabetes. Compared to the original placebo group, the median time without diabetes has been extended by 3.5 years in the lifestyle group and 2.5 years in the metformin group.
“For generations, our parents and those who have in front of them told us to eat our vegetables and do more exercise,” said Lynn Goldman, Michael dean and Lori Milken of George Washington Universiy Milken Institute School of Public Health. “Now we have scientific evidence that even if you are waiting for quarantine to change your diet and your activity levels, you can add many years of life without diabetes and all the conditions of deactivation that accompany it.”
Researchers from the George Washington University Biostatistes Center as well as researchers from the National Institutes of Health and 28 other institutions and clinical sites across the United States published the study on April 28 in the journal The Lancet Diabetes & Endocrinology.
The original DPP clinical trial began in 1996, when participants were 51 years old, on average and 45% identified as members of American minority groups who are particularly affected by type 2. Diabetes of type 2.. The long-term advantages of the two interventions have extended into all racial-ethnic groups included in the study.
In summary, the significant intervention effects observed during the first years of the trial led to a sustained reduction in the development of diabetes over 21 years, increasing the years without diabetes. Despite the challenges of maintaining intensive life -style and intensive long -term medicine interventions, even short -term interventions have lasting advantages, according to the study.
The GW Biostatistes Center coordinated the major multicenter study nationwide and managed and analyzed data from other participating institutions and clinical sites. Marinella Temprosa led a team at GW Biostatistes Center, which is based at the GW Milken Institute School of Public Health.
“The DPP and its long -term follow -up study benefited from the collective dedication of participants on all sites and continued to show that lifestyle and metformin are effective preventive strategies of diabetes,” said Temprosa. “The DPP and its long -term follow -up study benefited from the faithful dedication of our volunteer participants.”
The diabetes prevention program and its long -term follow -up were generously funded by the National Institute of Diabetes and digestive and renal diseases of the National Institutes of Health and other agencies. The longer -term monitoring of participants in the study for the development of additional age -related conditions, including Alzheimer’s disease, has been financed mainly by the National Institute on Aging. Investigators are grateful to NIHs for their support for this work.
Study, Long -term effects and heterogeneity of the effects of lifestyle and metformin interventions on the impact of type 2 over 21 years in the American diabetes prevention program randomized clinical trialwas published on April 28 in Lancet Diabetes & Endocrinology.
-Gw-